CPC
EVFM

Congress Park Capital’s Evofem Biosciences, Inc. Common Stock EVFM Stock Holding History

Congress Park Capital’s Portfolio EVFM Stock Details EVFM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-967
Closed -$11K – 153
2021
Q3 		$11K Hold
967
– – 0.01% 136
2021
Q2 		$16K Buy
+967
New +$18.3K 0.01% 137

Other funds holding EVFM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
FWSM
First Wilshire Securities Management Pasadena, California $444M AUM 42.88% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Congress Park Capital's EVFM Position: Q4 2021 in Review

Congress Park Capital sold out of Evofem Biosciences, Inc. Common Stock (EVFM) in Q4 2021, closing a stake of 967 shares — an estimated $11K sold.

Congress Park Capital first reported a position in EVFM in Q2 2021 and held it in 2 quarters. The position peaked at $16K in Q2 2021. 62 funds tracked by Wall St. Rank hold EVFM as of Q4 2021.

  • Congress Park Capital reported no remaining Evofem Biosciences, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Congress Park Capital sold 967 Evofem Biosciences, Inc. Common Stock shares in Q4 2021, an estimated $11K.
  • Congress Park Capital first reported a position in Evofem Biosciences, Inc. Common Stock in Q2 2021 and held it in 2 quarters.
  • Congress Park Capital's Evofem Biosciences, Inc. Common Stock position peaked at $16K in Q2 2021.
  • 62 funds tracked by Wall St. Rank held Evofem Biosciences, Inc. Common Stock as of Q4 2021.

Based on Congress Park Capital's 13F filing for Q4 2021, filed 9 Feb 2022.